{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:54:12Z","timestamp":1789419252368,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004702","name":"Universit\u00e0 degli Studi di Genova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004702","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"DOI":"10.1007\/s40292-025-00764-3","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T19:20:26Z","timestamp":1765308026000},"page":"117-126","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dapagliflozin Reduces Ambulatory Arterial Stiffness Index in CKD Patients with and Without Diabetes Independently of Blood Pressure Control: Results from the GLUcose Transport and Renal PROtection in Chronic Kidney Disease (GLUTREPRO) Trial"],"prefix":"10.1007","volume":"33","clinical-trial-number":[{"clinical-trial-number":"nct05998837","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Elisa","family":"Russo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cappadona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Macci\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Di Vincenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Piaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Verzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Chirco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Garibotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4219-7043","authenticated-orcid":false,"given":"Francesca","family":"Viazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"issue":"13","key":"764_CR1","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(13):2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med"},{"issue":"1","key":"764_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","volume":"9","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Stef\u00e1nsson BV, Jongs N, Chertow GM, Greene T, Hou FF, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(1):22\u201331. https:\/\/doi.org\/10.1016\/S2213-8587(20)30369-7.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"764_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S2213-8587(23)00321-2","volume":"12","author":"EMPA-KIDNEY Collaborative Group","year":"2024","unstructured":"EMPA-KIDNEY Collaborative Group. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. Lancet Diabetes Endocrinol. 2024;12(1):39\u201350. https:\/\/doi.org\/10.1016\/S2213-8587(23)00321-2.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"764_CR4","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2337\/dc18-2207","volume":"42","author":"PI Georgianos","year":"2019","unstructured":"Georgianos PI, Agarwal R. Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide. Diabetes Care. 2019;42(4):693\u2013700. https:\/\/doi.org\/10.2337\/dc18-2207.","journal-title":"Diabetes Care"},{"issue":"4","key":"764_CR5","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.120.048740","volume":"143","author":"N Ye","year":"2021","unstructured":"Ye N, Jardine MJ, Oshima M, Hockham C, Heerspink HJL, Agarwal R, et al. Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: insights from the CREDENCE trial. Circulation. 2021;143(4):1735\u201349. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.048740.","journal-title":"Circulation"},{"issue":"6","key":"764_CR6","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1161\/HYPERTENSIONAHA.116.07703","volume":"68","author":"G Mancia","year":"2016","unstructured":"Mancia G, Cannon CP, Tikkanen I, Zeller C, Ley L, Woerle HJ, et al. Impact of Empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication. Hypertension. 2016;68(6):1355\u201364. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.07703.","journal-title":"Hypertension"},{"issue":"14","key":"764_CR7","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1093\/eurheartj\/ehae751","volume":"46","author":"FH Messerli","year":"2025","unstructured":"Messerli FH, Schoenenberger-Berzins R, Burnier M. SGLT2 inhibitors: not for hypertension but exceedingly useful in hypertension. Eur Heart J. 2025;46(14):1318\u201320. https:\/\/doi.org\/10.1093\/eurheartj\/ehae751.","journal-title":"Eur Heart J"},{"issue":"2","key":"764_CR8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.atherosclerosis.2015.05.007","volume":"241","author":"C Vlachopoulos","year":"2015","unstructured":"Vlachopoulos C, Xaplanteris P, Aboyans V, Brodmann M, C\u00edfkov\u00e1 R, Cosentino F, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis. 2015;241(2):507\u201332. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.05.007.","journal-title":"Atherosclerosis"},{"issue":"1","key":"764_CR9","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(1):3021\u2013104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339.","journal-title":"Eur Heart J"},{"key":"764_CR10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ijcard.2009.04.027","volume":"138","author":"S Sakuragi","year":"2010","unstructured":"Sakuragi S, Abhayaratna WP. Arterial stiffness: methods of measurement, physiologic determinants and prediction of cardiovascular outcomes. Int J Cardiol. 2010;138:112\u20138. https:\/\/doi.org\/10.1016\/j.ijcard.2009.04.027.","journal-title":"Int J Cardiol"},{"issue":"8","key":"764_CR11","doi-asserted-by":"publisher","first-page":"732","DOI":"10.5551\/jat.RV17043","volume":"27","author":"A Saiki","year":"2020","unstructured":"Saiki A, Ohira M, Yamaguchi T, Nagayama D, Shimizu N, Shirai K, et al. New horizons of arterial stiffness developed using cardio-ankle vascular index (CAVI). J Atheroscler Thromb. 2020;27(8):732\u201348. https:\/\/doi.org\/10.5551\/jat.RV17043.","journal-title":"J Atheroscler Thromb"},{"issue":"4","key":"764_CR12","doi-asserted-by":"publisher","first-page":"488","DOI":"10.4067\/s0034-98872020000400488","volume":"148","author":"D Lancellotti","year":"2020","unstructured":"Lancellotti D, Abarca A, Jorquera J, Lobos C, Aguilera D, S\u00c1nchez N. Ambulatory arterial stiffness index in diabetic patients. Rev Med Chil. 2020;148(4):488\u201395. https:\/\/doi.org\/10.4067\/s0034-98872020000400488.","journal-title":"Rev Med Chil"},{"issue":"3","key":"764_CR13","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1161\/01.HYP.0000236599.91051.1e","volume":"48","author":"G Leoncini","year":"2006","unstructured":"Leoncini G, Ratto E, Viazzi F, Vaccaro V, Parodi A, Falqui V, et al. Increased ambulatory arterial stiffness index is associated with target organ damage in primary hypertension. Hypertension. 2006;48(3):397\u2013403. https:\/\/doi.org\/10.1161\/01.HYP.0000236599.91051.1e.","journal-title":"Hypertension"},{"issue":"2","key":"764_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.atherosclerosis.2012.03.039","volume":"224","author":"A Kollias","year":"2012","unstructured":"Kollias A, Stergiou GS, Dolan E, O\u2019Brien E. Ambulatory arterial stiffness index: a systematic review and meta-analysis. Atherosclerosis. 2012;224(2):291\u2013301. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2012.03.039.","journal-title":"Atherosclerosis"},{"issue":"2","key":"764_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/jch.14755","volume":"26","author":"CJ Boos","year":"2024","unstructured":"Boos CJ, Hein A, Khattab A. Ambulatory arterial stiffness index, mortality, and adverse cardiovascular outcomes; systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2024;26(2):89\u2013101. https:\/\/doi.org\/10.1111\/jch.14755.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"9","key":"764_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58091167","volume":"58","author":"D Patoulias","year":"2022","unstructured":"Patoulias D, Papadopoulos C, Zografou I, Katsimardou A, Karagiannis A, Doumas M. Effect of empagliflozin and dapagliflozin on ambulatory arterial stiffness in patients with type 2 diabetes mellitus and cardiovascular co-morbidities: a prospective, observational study. Medicina (Kaunas). 2022;58(9):1167. https:\/\/doi.org\/10.3390\/medicina58091167.","journal-title":"Medicina (Kaunas)"},{"issue":"2","key":"764_CR17","doi-asserted-by":"publisher","first-page":"2304667","DOI":"10.1080\/07853890.2024.2304667","volume":"55","author":"P Stachteas","year":"2023","unstructured":"Stachteas P, Karakasis P, Patoulias D, Clemenza F, Fragakis N, Rizzo M. The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis. Ann Med. 2023;55(2):2304667. https:\/\/doi.org\/10.1080\/07853890.2024.2304667.","journal-title":"Ann Med"},{"issue":"12","key":"764_CR18","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/dom.12572","volume":"17","author":"R Chilton","year":"2015","unstructured":"Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17(12):1180\u201393. https:\/\/doi.org\/10.1111\/dom.12572.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"764_CR19","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1097\/HJH.0000000000004007","volume":"43","author":"SF Nielsen","year":"2025","unstructured":"Nielsen SF, Duus CL, Buus NH, Bech JN, Mose FH. The effects of empagliflozin on systemic haemodynamic function: three randomized, placebo-controlled trials. J Hypertens. 2025;43(6):1021\u20139. https:\/\/doi.org\/10.1097\/HJH.0000000000004007.","journal-title":"J Hypertens"},{"key":"764_CR20","unstructured":"Russo E, Venturelli E, Di Vincenzo J, Macci\u00f2 L, Esposito P, Cappadona F, Ferrazzi G, Grillo R, Damasio MB, Garibotto G, Viazzi F. Dapagliflozin mitigates medullary hypoxia in CKD patients: Analysis of BOLD MRI Renal Data from the Randomized GLUTREPRO Trial. K360, (in press)"},{"issue":"Suppl 1","key":"764_CR21","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.2337\/dc21-S006","volume":"44","author":"American Diabetes Association 6","year":"2021","unstructured":"American Diabetes Association 6. Glycemic targets: Standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S73\u201384. https:\/\/doi.org\/10.2337\/dc21-S006.","journal-title":"Diabetes Care"},{"issue":"5","key":"764_CR22","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(5):604\u201312. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006.","journal-title":"Ann Intern Med"},{"issue":"2","key":"764_CR23","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1161\/CIRCRESAHA.121.318061","volume":"128","author":"P Boutouyrie","year":"2021","unstructured":"Boutouyrie P, Chowienczyk P, Humphrey JD, Mitchell GF. Arterial stiffness and cardiovascular risk in hypertension. Circ Res. 2021;128(2):864\u201386. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318061.","journal-title":"Circ Res"},{"issue":"3","key":"764_CR24","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2337\/dc12-0850","volume":"36","author":"S Theilade","year":"2013","unstructured":"Theilade S, Lajer M, Persson F, Joergensen C, Rossing P. Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes. Diabetes Care. 2013;36(3):715\u201321. https:\/\/doi.org\/10.2337\/dc12-0850.","journal-title":"Diabetes Care"},{"issue":"9","key":"764_CR25","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.122.059150","volume":"146","author":"Y Lytvyn","year":"2022","unstructured":"Lytvyn Y, Kimura K, Peter N, Lai V, Tse J, Cham L, et al. Renal and vascular effects of combined SGLT2 and angiotensin-converting enzyme inhibition. Circulation. 2022;146(9):450\u201362. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059150.","journal-title":"Circulation"},{"issue":"8","key":"764_CR26","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","volume":"9","author":"JA Requena-Ib\u00e1\u00f1ez","year":"2021","unstructured":"Requena-Ib\u00e1\u00f1ez JA, Santos-Gallego CG, Rodriguez-Cordero A, Vargas-Delgado AP, Mancini D, Sartori S, et al. Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study. JACC Heart Fail. 2021;9(8):578\u201389. https:\/\/doi.org\/10.1016\/j.jchf.2021.04.014.","journal-title":"JACC Heart Fail"},{"issue":"1","key":"764_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01235-4","volume":"20","author":"SR Nandula","year":"2021","unstructured":"Nandula SR, Kundu N, Awal HB, Brichacek B, Fakhri M, Aimalla N, et al. Role of canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes. Cardiovasc Diabetol. 2021;20(1):44. https:\/\/doi.org\/10.1186\/s12933-021-01235-4.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"764_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2024.108781","volume":"38","author":"EC Rizos","year":"2024","unstructured":"Rizos EC, Tagkas CF, Asimakopoulos AI, Tsimihodimos V, Anastasiou G, Rizzo M, et al. The effect of SGLT2 inhibitors and GLP1 receptor agonists on arterial stiffness: a meta-analysis of randomized controlled trials. J Diabetes Complic. 2024;38(7):108781. https:\/\/doi.org\/10.1016\/j.jdiacomp.2024.108781.","journal-title":"J Diabetes Complic"},{"issue":"14","key":"764_CR29","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1093\/eurheartj\/ehae938","volume":"46","author":"M B\u00f6hm","year":"2025","unstructured":"B\u00f6hm M, Butler J, Coats A, Lauder L, Mahfoud F, Filippatos G, et al. Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. Eur Heart J. 2025;46(14):1304\u201317. https:\/\/doi.org\/10.1093\/eurheartj\/ehae938.","journal-title":"Eur Heart J"},{"issue":"6","key":"764_CR30","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jacasi.2023.10.010","volume":"4","author":"X Tian","year":"2023","unstructured":"Tian X, Chen S, Xia X, Xu Q, Zhang Y, Zhang X, et al. Causal association of arterial stiffness with the risk of chronic kidney disease. JACC Asia. 2023;4(6):444\u201353. https:\/\/doi.org\/10.1016\/j.jacasi.2023.10.010.","journal-title":"JACC Asia."},{"issue":"3","key":"764_CR31","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1161\/HYPERTENSIONAHA.121.17962","volume":"79","author":"S Laurent","year":"2022","unstructured":"Laurent S, Agabiti-Rosei C, Bruno RM, Rizzoni D. Microcirculation and macrocirculation in hypertension: A dangerous cross-link? Hypertension. 2022;79(3):479\u201390. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.121.17962.","journal-title":"Hypertension"},{"issue":"2","key":"764_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s40200-025-01647-z","volume":"24","author":"S Partalidou","year":"2025","unstructured":"Partalidou S, Patoulias D, Pantekidis I, Kefas A, Doumas M, Gkaliagkousi E, et al. The cross-talk between arterial stiffness and microvascular complications in diabetes mellitus: a systematic review of the literature. J Diabetes Metab Disord. 2025;24(2):144. https:\/\/doi.org\/10.1007\/s40200-025-01647-z.","journal-title":"J Diabetes Metab Disord"},{"issue":"1","key":"764_CR33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","volume":"83","author":"V Vallon","year":"2021","unstructured":"Vallon V, Verma S. Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu Rev Physiol. 2021;83(1):503\u201328. https:\/\/doi.org\/10.1146\/annurev-physiol-031620-095920.","journal-title":"Annu Rev Physiol"},{"issue":"1","key":"764_CR34","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ekir.2024.10.019","volume":"10","author":"SF Nielsen","year":"2024","unstructured":"Nielsen SF, Duus CL, Buus NH, Bech JN, Mose FH. Randomized, placebo-controlled trial on the renal and systemic hemodynamic effects of empagliflozin. Kidney Int Rep. 2024;10(1):134\u201344. https:\/\/doi.org\/10.1016\/j.ekir.2024.10.019.","journal-title":"Kidney Int Rep."},{"issue":"3","key":"764_CR35","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00424-007-0212-8","volume":"454","author":"S Reitsma","year":"2007","unstructured":"Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, Oude Egbrink MG. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch. 2007;454(3):345\u201359. https:\/\/doi.org\/10.1007\/s00424-007-0212-8.","journal-title":"Pflugers Arch"},{"issue":"4","key":"764_CR36","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1681\/ASN.2014050430","volume":"26","author":"RH Olde Engberink","year":"2015","unstructured":"Olde Engberink RH, Rorije NM, Homan van der Heide JJ, van den Born BJ, Vogt L. Role of the vascular wall in sodium homeostasis and salt sensitivity. J Am Soc Nephrol. 2015;26(4):777\u201383. https:\/\/doi.org\/10.1681\/ASN.2014050430.","journal-title":"J Am Soc Nephrol"},{"issue":"25","key":"764_CR37","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","volume":"148","author":"M Packer","year":"2023","unstructured":"Packer M, Wilcox CS, Testani JM. Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes. Circulation. 2023;148(25):354\u201372. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.064346.","journal-title":"Circulation"},{"key":"764_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1494882","volume":"11","author":"YR Chen","year":"2024","unstructured":"Chen YR, Zhu FY, Zhou R. SGLT2 inhibitors for alleviating heart failure through non-hypoglycemic mechanisms. Front Cardiovasc Med. 2024;11:1494882. https:\/\/doi.org\/10.3389\/fcvm.2024.1494882.","journal-title":"Front Cardiovasc Med"},{"key":"764_CR39","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00395-025-01115-y","volume":"120","author":"M Wang","year":"2025","unstructured":"Wang M, Preckel B, Zuurbier CJ, Weber NC. Effects of SGLT2 inhibitors on ion channels in heart failure: focus on the endothelium. Basic Res Cardiol. 2025;120:779\u201398. https:\/\/doi.org\/10.1007\/s00395-025-01115-y.","journal-title":"Basic Res Cardiol"},{"key":"764_CR40","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/cvr\/cvae257","volume":"121","author":"A Mroueh","year":"2025","unstructured":"Mroueh A, Algara-Suarez P, Fakih W, Gong DS, Matsushita K, Park SH, et al. SGLT2 expression in human vasculature and heart correlates with low-grade inflammation and causes eNOS-NO\/ROS imbalance. Cardiovasc Res. 2025;121:643\u201357. https:\/\/doi.org\/10.1093\/cvr\/cvae257.","journal-title":"Cardiovasc Res"},{"key":"764_CR41","doi-asserted-by":"publisher","first-page":"C1150","DOI":"10.1152\/ajpcell.00569.2025","volume":"329","author":"BR G\u00f3es-Santos","year":"2025","unstructured":"G\u00f3es-Santos BR, Castro PC, Girardi ACC, Antunes-Correa LM, Davel AP. Vascular effects of SGLT2 inhibitors: evidence and mechanisms. Am J Physiol Cell Physiol. 2025;329:C1150\u201360. https:\/\/doi.org\/10.1152\/ajpcell.00569.2025.","journal-title":"Am J Physiol Cell Physiol"},{"key":"764_CR42","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors. JACC: Basic to Translational Science. 2020;5:632\u201344. https:\/\/doi.org\/10.1016\/j.jacbts.2020.02.004.","journal-title":"JACC: Basic to Translational Science"}],"container-title":["High Blood Pressure & Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-025-00764-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40292-025-00764-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-025-00764-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T10:55:04Z","timestamp":1770548104000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40292-025-00764-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["764"],"URL":"https:\/\/doi.org\/10.1007\/s40292-025-00764-3","relation":{},"ISSN":["1179-1985"],"issn-type":[{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors are required to disclose any possible conflicts of interest. All forms of support and financial involvement (e.g. employment, consultancies, honoraria, stock ownership and options, expert testimony, grants or patents received or pending, royalties) which took place in the previous three years should be listed, regardless of their potential relevance to the paper. Also the nonfinancial relationships (personal, political, or professional) that may potentially influence the writing of the manuscript should be declared. If there is no conflict of interest, please state: \u201cThe authors have no conflicts of interest to declare.\u201d","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the local institutional review committee (the Ethic Committee of the Ligurian Region CE 150193 with the ID D169AL00005) and authorized by the Italian Drug Agency (AIFA). The study was registered in the EU Clinical Trials Register\u00a0(EudraCT: 2020-004835-26) and online at the\n                      \n                      (Unique identifier: NCT05998837, 13th April 2021).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This study was conducted in accordance with the GCP\/ICH E6 Guidelines and the principles of the Declaration of Helsinki and all patients provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}]}}